CLINICAL TRIAL NEWS

New Programs

Advances In Medicine and Desert Medical Advances offer the community new treatment programs for many important diseases.  All these programs are free and authorized by the FDA. 

1.     New Asthma Therapy.

·        Reslizumab, Tralokinumab and Lebrikizumab. Brand new categories of non-steroid medication for the treatment of moderate to severe asthma.

·        New Symbicort device. A new improved administration device for an already FDA approved long acting beta agonist/anti-inflammatory medication. 

2.     New Treatment for Chronic Obstructive Pulmonary Disease, COPD.

·        Fluticasone Furoate/Vilanterol inhalation powder. A next generation long acting bronchodilator (taken only once a day)/anti-inflammatory inhaler combination to help treat COPD, and hopefully lower heart disease risk for patients with heart disease risk factors (including hypertension, high cholesterol, diabetes, heart problems, etc.)

3.     New Treatment for Systemic Sclerosis (Scleroderma) with Interstitial Lung Disease.

·        Pomalidomide. A new medication class of immunomodulatory agents is being studied in the treatment of lung disease in systemic sclerosis

4.     New Protein Therapies for Rheumatoid Arthritis.

• New protein therapy is available to patients with rheumatoid arthritis.  These natural proteins of the body suppress inflammation with no serious side effects related to the stomach, liver, or kidney.  The programs will assess how well the new protein therapies control rheumatoid arthritis.